Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, has embarked on its ...

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three ...

The Nifty Pharma has gained around 37% year to date. The growth continues to be led by the US sales and well supported by ...

The SBTi has validated and approved India's Piramal Pharma’s near-term greenhouse gas (GHG) emission reduction targets.

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in ...

The company is involved in the manufacturing and global marketing of a diverse range of pharmaceuticals both in India and internationally. Dr. Reddy’s Labs recently acquired MenoLabs from Amyris ...

The Indian biotechnology sector is a rapidly advancing segment within the economy, often referred to as a sunrise sector due ...

Aushadhi Kendra is a dedicated outlet that sells generic medicines at affordable rates. Generic medicines are 50-90% cheaper ...

India faces a rising concern as diabetes increasingly links to neurodegenerative diseases like dementia and Alzheimer’s. With ...

The pharma major informed that a meeting of its board is scheduled to be held on Friday, 20 September 2024 to mull the fund raising proposal for an amount as may be decided.

With this commitment, Piramal Pharma becomes the third pharmaceutical company in India to have its emission reduction targets approved by the SBTi. The SBTi is a collaborative initiative that ...

Lupin Limited partners with Takeda to launch Vonoprazan tablets in India, targeting acid peptic disorders with Lupivon brand.